| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 45 | 2024 | 1199 | 6.970 |
Why?
|
| Transplantation Conditioning | 15 | 2024 | 323 | 2.660 |
Why?
|
| Severe Combined Immunodeficiency | 10 | 2024 | 105 | 1.940 |
Why?
|
| Graft vs Host Disease | 20 | 2024 | 543 | 1.900 |
Why?
|
| Granulomatous Disease, Chronic | 5 | 2023 | 65 | 1.450 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 4 | 2020 | 145 | 1.410 |
Why?
|
| Alemtuzumab | 4 | 2023 | 88 | 1.290 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2019 | 52 | 1.210 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2023 | 47 | 1.050 |
Why?
|
| T-Lymphocytes | 15 | 2024 | 1697 | 0.970 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2021 | 201 | 0.900 |
Why?
|
| Transplantation, Homologous | 15 | 2024 | 659 | 0.780 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2020 | 22 | 0.760 |
Why?
|
| Agammaglobulinemia | 2 | 2022 | 39 | 0.760 |
Why?
|
| Bone Marrow Transplantation | 5 | 2017 | 578 | 0.750 |
Why?
|
| Child, Preschool | 31 | 2024 | 13916 | 0.720 |
Why?
|
| Unrelated Donors | 6 | 2021 | 82 | 0.690 |
Why?
|
| Thiotepa | 1 | 2020 | 15 | 0.690 |
Why?
|
| Complement C3b | 1 | 2019 | 7 | 0.680 |
Why?
|
| Complement Factor B | 1 | 2019 | 11 | 0.680 |
Why?
|
| Complement Pathway, Alternative | 1 | 2019 | 15 | 0.670 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 99 | 0.650 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 250 | 0.640 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2023 | 141 | 0.630 |
Why?
|
| Child | 38 | 2024 | 24264 | 0.630 |
Why?
|
| BK Virus | 2 | 2018 | 59 | 0.610 |
Why?
|
| Infant | 27 | 2024 | 12379 | 0.600 |
Why?
|
| Organophosphonates | 1 | 2018 | 19 | 0.600 |
Why?
|
| Cytosine | 1 | 2018 | 56 | 0.590 |
Why?
|
| Plasma Exchange | 1 | 2018 | 84 | 0.570 |
Why?
|
| Graft vs Host Reaction | 1 | 2017 | 9 | 0.570 |
Why?
|
| Cystitis | 1 | 2018 | 50 | 0.570 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 826 | 0.560 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 134 | 0.560 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 90 | 0.560 |
Why?
|
| Infection Control | 1 | 2018 | 160 | 0.550 |
Why?
|
| Adolescent | 30 | 2024 | 19132 | 0.540 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 238 | 0.510 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 481 | 0.500 |
Why?
|
| Leukemia | 5 | 2024 | 375 | 0.490 |
Why?
|
| Tissue Donors | 4 | 2019 | 496 | 0.480 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 2055 | 0.460 |
Why?
|
| Busulfan | 2 | 2024 | 44 | 0.450 |
Why?
|
| Antiviral Agents | 2 | 2023 | 744 | 0.440 |
Why?
|
| Humans | 61 | 2024 | 123311 | 0.430 |
Why?
|
| Virus Diseases | 4 | 2023 | 279 | 0.390 |
Why?
|
| Biomarkers | 2 | 2019 | 2950 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 716 | 0.340 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 260 | 0.330 |
Why?
|
| Male | 33 | 2024 | 60285 | 0.330 |
Why?
|
| Neonatal Screening | 4 | 2024 | 184 | 0.330 |
Why?
|
| Caspase 9 | 3 | 2015 | 75 | 0.320 |
Why?
|
| Infant, Newborn | 14 | 2024 | 8118 | 0.320 |
Why?
|
| Retrospective Studies | 19 | 2024 | 16066 | 0.320 |
Why?
|
| Allografts | 3 | 2018 | 192 | 0.320 |
Why?
|
| Immune Reconstitution | 2 | 2018 | 6 | 0.300 |
Why?
|
| Female | 31 | 2024 | 65618 | 0.300 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5050 | 0.300 |
Why?
|
| Cytomegalovirus | 3 | 2019 | 269 | 0.280 |
Why?
|
| Gangliosides | 1 | 2007 | 70 | 0.260 |
Why?
|
| DNA Viruses | 2 | 2017 | 33 | 0.250 |
Why?
|
| Adoptive Transfer | 2 | 2019 | 237 | 0.250 |
Why?
|
| Young Adult | 13 | 2024 | 8871 | 0.240 |
Why?
|
| Adult | 15 | 2024 | 29087 | 0.240 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 123 | 0.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 805 | 0.220 |
Why?
|
| Lymphopenia | 1 | 2024 | 36 | 0.220 |
Why?
|
| beta-Thalassemia | 1 | 2023 | 28 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 34 | 0.210 |
Why?
|
| Thymus Gland | 1 | 2023 | 100 | 0.210 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 289 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 3 | 2019 | 217 | 0.200 |
Why?
|
| Early Diagnosis | 1 | 2023 | 179 | 0.200 |
Why?
|
| Acute Disease | 4 | 2022 | 1093 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 146 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 31 | 0.200 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 157 | 0.190 |
Why?
|
| Survival Rate | 4 | 2020 | 2001 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2023 | 243 | 0.190 |
Why?
|
| Interferon Type I | 1 | 2021 | 107 | 0.180 |
Why?
|
| Transplant Recipients | 2 | 2020 | 209 | 0.180 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 422 | 0.180 |
Why?
|
| Lymphoma | 1 | 2024 | 324 | 0.180 |
Why?
|
| Recurrence | 6 | 2023 | 1419 | 0.180 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 10 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2018 | 46 | 0.180 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2011 | 38 | 0.170 |
Why?
|
| Osteoblasts | 2 | 2013 | 149 | 0.170 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 202 | 0.170 |
Why?
|
| Complement Activation | 1 | 2019 | 52 | 0.170 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 25 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2017 | 324 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2023 | 6032 | 0.160 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 52 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 294 | 0.160 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2018 | 19 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 859 | 0.160 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 40 | 0.150 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 58 | 0.150 |
Why?
|
| Cytokines | 2 | 2021 | 1284 | 0.150 |
Why?
|
| Chimerism | 1 | 2018 | 28 | 0.150 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 32 | 0.150 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 28 | 0.150 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 216 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 100 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 162 | 0.150 |
Why?
|
| Antigens, Viral | 2 | 2017 | 435 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2019 | 220 | 0.140 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 19 | 0.140 |
Why?
|
| Immune System Diseases | 1 | 2017 | 43 | 0.140 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2017 | 65 | 0.140 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 13 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 335 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 45 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 130 | 0.140 |
Why?
|
| Metapneumovirus | 1 | 2017 | 51 | 0.140 |
Why?
|
| Treatment Outcome | 10 | 2024 | 12168 | 0.140 |
Why?
|
| Mutation | 4 | 2022 | 5768 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 321 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 224 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 4515 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2022 | 512 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1313 | 0.130 |
Why?
|
| Diarrhea | 1 | 2017 | 315 | 0.130 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2015 | 49 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 4 | 2023 | 670 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2018 | 305 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 473 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 769 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 367 | 0.120 |
Why?
|
| Incidence | 2 | 2023 | 3052 | 0.120 |
Why?
|
| Phosphoglucomutase | 1 | 2014 | 7 | 0.120 |
Why?
|
| Bone Diseases, Developmental | 1 | 2014 | 62 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 524 | 0.110 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2014 | 39 | 0.110 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2013 | 19 | 0.110 |
Why?
|
| Epitopes | 1 | 2015 | 430 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2014 | 124 | 0.110 |
Why?
|
| Viruses | 1 | 2014 | 123 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 70 | 0.100 |
Why?
|
| Transgenes | 1 | 2014 | 335 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 862 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3240 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 320 | 0.100 |
Why?
|
| Flow Cytometry | 3 | 2015 | 804 | 0.100 |
Why?
|
| Exome | 1 | 2017 | 1040 | 0.100 |
Why?
|
| Herpesviridae Infections | 1 | 2013 | 142 | 0.100 |
Why?
|
| Sibling Relations | 1 | 2011 | 13 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2805 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 286 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2018 | 997 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1877 | 0.090 |
Why?
|
| Lung | 1 | 2019 | 1466 | 0.090 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2011 | 66 | 0.090 |
Why?
|
| Genome, Human | 1 | 2018 | 1265 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 1752 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 284 | 0.090 |
Why?
|
| Educational Status | 1 | 2011 | 270 | 0.090 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 501 | 0.090 |
Why?
|
| Genotype | 3 | 2023 | 2533 | 0.090 |
Why?
|
| Organic Chemicals | 3 | 2015 | 59 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 796 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 404 | 0.080 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 297 | 0.070 |
Why?
|
| Middle Aged | 7 | 2024 | 26075 | 0.070 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2007 | 7 | 0.070 |
Why?
|
| Risk Factors | 2 | 2017 | 10042 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2007 | 121 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2013 | 3044 | 0.060 |
Why?
|
| Graft Survival | 1 | 2008 | 530 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2007 | 295 | 0.060 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 41 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 124 | 0.060 |
Why?
|
| Adipose Tissue | 1 | 2007 | 464 | 0.060 |
Why?
|
| Canada | 1 | 2023 | 295 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2024 | 2307 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2017 | 1473 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 74 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 881 | 0.050 |
Why?
|
| I-kappa B Kinase | 1 | 2022 | 61 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 228 | 0.050 |
Why?
|
| Pedigree | 2 | 2017 | 1577 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 49 | 0.050 |
Why?
|
| Quality of Life | 1 | 2011 | 1932 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2022 | 108 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 155 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2021 | 177 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 19174 | 0.040 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Tissue Banks | 1 | 2019 | 26 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 539 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 115 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 393 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2019 | 243 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 37 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 50 | 0.040 |
Why?
|
| Heredity | 1 | 2017 | 15 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 66 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 136 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 81 | 0.040 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 58 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 269 | 0.030 |
Why?
|
| Neurons | 1 | 2007 | 1938 | 0.030 |
Why?
|
| Sepsis | 1 | 2020 | 476 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 301 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1118 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1390 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 295 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 605 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 499 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1232 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 667 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 756 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 103 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 381 | 0.030 |
Why?
|
| Siblings | 1 | 2015 | 196 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1498 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 224 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2014 | 328 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 517 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 549 | 0.030 |
Why?
|
| North America | 1 | 2013 | 239 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 33822 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 114 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 510 | 0.030 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 85 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 747 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 137 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 152 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 3568 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2017 | 660 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2013 | 153 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2115 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 482 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 411 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 645 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1638 | 0.020 |
Why?
|
| Mice | 3 | 2013 | 17550 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1166 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3382 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 609 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3680 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 357 | 0.020 |
Why?
|
| Stem Cells | 1 | 2014 | 702 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2011 | 217 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 4709 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 1314 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2771 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 501 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4226 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1259 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3081 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 394 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 3722 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 1787 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 4357 | 0.010 |
Why?
|
| Pregnancy | 1 | 2017 | 7156 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1688 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 6228 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2014 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 2398 | 0.010 |
Why?
|